Abstract

Breast cancer is the most frequent cancer in women, affecting around 2.1 million people per year. The type of breast cancer and the severity of the disease determine the pharmacological treatment. However, continued use of a medicine might lead to resistance, necessitating the creation of other drugs. Breast cancer in the elderly has become a public health concern, and treatment must be redesigned in order to de-escalate the disease. The justification for a phase 3 randomised study to examine less burdensome adjuvant procedures that are nonetheless efficacious and efficient is outlined in our research. Breast cancer in young women is a regular occurrence in China. Clinically and pathologically, young breast cancer is aggressive. Issues such as surgical procedure selection, early amenorrhea, and fertility preservation may have medical, psychological, and social consequences for young females with breast cancer. As a result, a comprehensive approach to diagnosis and therapy is required.